Fate Therapeutics (NASDAQ:FATE) Earns Neutral Rating from Wedbush
Wedbush reissued their neutral rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a research report report published on Monday, Marketbeat reports. The brokerage currently has a $7.00 price objective on the biopharmaceutical company’s stock. Wedbush also issued estimates for Fate Therapeutics’ Q1 2024 earnings at ($0.42) EPS, Q2 2024 earnings at ($0.43) […]
More Stories
CK Hutchison Holdings Limited (OTCMKTS:CKHUY) Sees Large Growth in Short Interest
CK Hutchison Holdings Limited (OTCMKTS:CKHUY – Get Free Report) was the recipient of a significant growth in short interest in...
Short Interest in Elevai Labs, Inc. (NASDAQ:ELAB) Expands By 438.9%
Elevai Labs, Inc. (NASDAQ:ELAB – Get Free Report) saw a significant increase in short interest in December. As of December...
Canada Carbon (CVE:CCB) Shares Down 33.3% – Here’s What Happened
Canada Carbon Inc. (CVE:CCB – Get Free Report) dropped 33.3% during trading on Friday . The company traded as low...
Sotherly Hotels Inc. (NASDAQ:SOHO) Sees Large Increase in Short Interest
Sotherly Hotels Inc. (NASDAQ:SOHO – Get Free Report) was the target of a large growth in short interest in the...
Soluna Holdings, Inc. (NASDAQ:SLNH) Short Interest Up 78.3% in December
Soluna Holdings, Inc. (NASDAQ:SLNH – Get Free Report) was the target of a large growth in short interest in the...
Sezzle Inc. (NASDAQ:SEZL) Sees Large Increase in Short Interest
Sezzle Inc. (NASDAQ:SEZL – Get Free Report) was the recipient of a significant growth in short interest during the month...